Fig. 7: OSW-1 combined with anti-PD-1 antibody enhances tumor suppression and antitumor immune response.

A–F C57BL/6 mice were injected s.c. with 5 × 10⁵ WT MC38 cells. After tumor growth for 7 days, mice were treated with OSW-1 (i.p.; 5 μg/kg), anti-mouse-PD-1 (i,p.; 150 μg/dose), or their combination as indicated in (A). A Tumor volume at indicated time points with statistical significance for indicated comparisons (n = 11–12 in each group). B Representative tumors at the end of the experiment. Scale bars, 10 mm. C–F Flow cytometry analysis of infiltrating lymphocytes in tumors resected on day 11 (n = 6 in each group): C CD3⁺/CD45⁺, D CD8⁺/CD45⁺, E CD11c⁺/CD45⁺, and F CD25⁺/FoxP3⁺/CD4⁺. G–L C57BL/6 mice were injected s.c. with 5 × 10⁵ WT, p53-KO, or PUMA-KO MC38 cells. After tumor growth for 7 days, mice were treated with OSW-1 (i.p.; 5 μg/kg), anti-mouse-PD-1 (i,p.; 150 μg/dose), or their combination as indicated in (G). G Tumor volume at indicated time points with statistical significance for indicated comparisons (n = 7–12 in each group). H Representative tumors at the end of the experiment. Scale bars, 10 mm. I–L Flow cytometry analysis of infiltrating lymphocytes in tumors resected on day 11 (n = 6 in each group): I CD3⁺/CD45⁺, J CD8⁺/CD45⁺, K CD11c⁺/CD45⁺, and L CD25⁺/FoxP3⁺/CD4⁺. *, P < 0.05; **, P < 0.01; **, P < 0.001.